2020 was an interesting year for the biotech industry and the BioHealth Capital Region as we adjusted to continue moving forward during the COVID-19 Pandemic. While the biggest stories in terms of dollars were related to the Coronavirus and funding to create a vaccine in record time, that didn’t stop other biotech companies from working hard to develop their research, science, and/or devices.
Women In Bio is accepting applications for its Sixth Boardroom Ready Program, a classroom opportunity that provides training for female biopharma executives vying for a spot on a board of directors in the industry.
Lonza’s Walkersville, Maryland site is seeking new talent to support a growing portfolio of exciting projects. As part of this hiring campaign, the Walkersville site is hosting a Virtual Recruiting Event on January 26th so that job candidates can learn more about Lonza, its culture, and the opportunities available at the Walkersville location, which is just a short drive from downtown Frederick, Maryland, one the region’s most popular destinations.
Modavar Pharmaceuticals (Modavar), a wholly-owned subsidiary of Indian pharma giant Cadila Pharmaceuticals, recently opened a brand new, state-of-the-art, 22,000 square foot manufacturing facility in Frederick, Maryland, adding a prestigious new life science company to the blossoming Frederick biotech hub.
Clene Nanomedicine, one of Maryland’s Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the Nasdaq Exchange and $3.19 million that will be used to advance the company’s gold nanocrystal-based treatment for neurodegenerative diseases.
The COVID-19 pandemic has presented no shortage of challenges for Maryland businesses from managing a remote workforce to accessing volatile capital markets. The Maryland Tech Council (MTC) believes local companies can turn these challenges into long-term opportunities.
The pandemic changed everything. We live differently, behave differently, and have come to appreciate the little things we might have taken for granted before COVID-19 took hold in the BioHealth Capital Region (BHCR).
In early November, the Novavax COVID-19 vaccine received fast track designation by the Food and Drug Administration (FDA) and has begun its Phase 3 trials in the United States and Mexico.
Personalized and regenerative medicines are promising but they are complex to develop and require highly-flexible advanced manufacturing techniques that are still too manually intensive and costly.
CRB, a leading design-build firm specializing in tech and life science facilities, recently announced the launch of SlateXpace, a groundbreaking design-build solution for life science facilities. SlateXpace is a modular, multi-modal facility solution for the development and manufacture of Advanced Therapy Medicinal Products (ATMP) that offers life science organizations unprecedented construction speed, development flexibility, manufacturing adaptability, and budget control.
